Dyadic International (DYAI) SEC Filings: History & Chart

Dyadic International, Inc.(DYAI)

Biotechnology · Jupiter, FL

$0.45-0.00 (-0.29%)

Delayed quote: Oct 6, 2026, 2:37 PM EDT

About Dyadic International, Inc.

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.

Jupiter, FL

5 employees

www.dyadic.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark A. Emalfarb

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 25, 2026	Sep 25, 2026	View filing
EFFECT	Sep 18, 2026	Sep 21, 2026	View filing
424B3	Sep 18, 2026	Sep 18, 2026	View filing
S-1	Sep 11, 2026	Sep 11, 2026	View filing
SC 13G/A	Aug 17, 2026	Aug 17, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
424B5	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
4	Jul 24, 2026	Jul 24, 2026	View filing
8-K	Jul 24, 2026	Jul 24, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
SC 13G/A	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
DEFA14A	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
8-K	May 28, 2026	May 28, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
DEF 14A	May 12, 2026	May 12, 2026	View filing
SC 13G/A	May 11, 2026	May 11, 2026	View filing
SC 13G	May 11, 2026	May 11, 2026	View filing
PRE 14A	May 1, 2026	May 1, 2026	View filing
10-K/A	Apr 30, 2026	Apr 30, 2026	View filing
8-K	Mar 30, 2026	Mar 27, 2026	View filing
8-K	Mar 25, 2026	Mar 25, 2026	View filing
10-K	Mar 25, 2026	Mar 25, 2026	View filing
8-K	Mar 6, 2026	Mar 6, 2026	View filing
424B5	Mar 6, 2026	Mar 6, 2026	View filing

SEC Filings

Recent Filings